Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.37 |
| ▸ | DRD2 | P14416 | 4/20 | 0.36 |
| ▸ | DRD1 | P21728 | 4/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 2/20 | 0.35 |
| ▸ | HTR2A | P28223 | 3/20 | 0.33 |
| ▸ | NQO2 | P16083 | 1/20 | 0.32 |
| ▸ | ERN1 | O75460 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14647321 | 0.82 | MAOA (0.31) | CYP1A2 | |
| SCHEMBL14645681 | 0.81 | CYP1A2 (0.43) | KDM4ECYP1A2ADRA1ADRD2DRD1 | |
| SCHEMBL28032818 | 0.77 | KDM4E (0.41) | KDM4ECYP1A2ADRA1ADRD2DRD1 | |
| SCHEMBL20478842 | 0.76 | CYP1A2 (0.48) | KDM4ECYP1A2ADRA1ADRD2DRD1 | |
| SCHEMBL20478690 | 0.76 | CYP1A2 (0.48) | KDM4ECYP1A2ADRA1ADRD2DRD1 | |
| SCHEMBL14645603 | 0.75 | POLL (0.31) | — | |
| SCHEMBL20478732 | 0.72 | KDM4E (0.41) | KDM4ECYP1A2ADRA1ADRD2DRD1 | |
| SCHEMBL1321294 | 0.70 | ALDH1A1 (0.36) | KDM4E | |
| SCHEMBL20478635 | 0.70 | CYP1A2 (0.56) | KDM4ECYP1A2ADRA1ADRD2DRD1 | |
| SCHEMBL15822092 | 0.68 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2746301-B1 | Catalyst | BOREALIS AG (AT) | 2018-05-30 | — | — | EP | disclosed |
| EP-2746301-B1 | Catalyst | BOREALIS AG (AT) | 2018-05-30 | — | — | EP | disclosed |
| EP-2729479-B1 | CATALYSTS | BOREALIS AG (AT) | 2017-09-06 | — | — | EP | disclosed |
| EP-2729479-B1 | CATALYSTS | BOREALIS AG (AT) | 2017-09-06 | — | — | EP | disclosed |
| US-9630980-B2 | Asymmetrical ligands | BOREALIS AG (AT) | 2017-04-25 | — | — | US | disclosed |
| US-9630980-B2 | Asymmetrical ligands | BOREALIS AG (AT) | 2017-04-25 | — | — | US | disclosed |
| US-9630980-B2 | Asymmetrical ligands | BOREALIS AG (AT) | 2017-04-25 | — | — | US | disclosed |
| US-9598517-B2 | Catalysts | BOREALIS AG (AT) | 2017-03-21 | — | — | US | disclosed |
| US-20160024123-A1 | Asymmetrical Ligands | BOREALIS AG (AT) | 2016-01-28 | — | — | US | disclosed |
| US-20160024123-A1 | Asymmetrical Ligands | BOREALIS AG (AT) | 2016-01-28 | — | — | US | disclosed |
| US-9187583-B2 | Catalysts | BOREALIS AG (AT) | 2015-11-17 | — | — | US | disclosed |
| US-20140221584-A1 | CATALYSTS | BOREALIS AG (AT) | 2014-08-07 | — | — | US | disclosed |
| US-20140221584-A1 | CATALYSTS | BOREALIS AG (AT) | 2014-08-07 | — | — | US | disclosed |
| US-20140221584-A1 | CATALYSTS | BOREALIS AG (AT) | 2014-08-07 | — | — | US | disclosed |
| WO-2014096166-A1 | CATALYSTS | BOREALIS AG (AT) | 2014-06-26 | — | — | WO | disclosed |
| WO-2014096166-A1 | CATALYSTS | BOREALIS AG (AT) | 2014-06-26 | — | — | WO | disclosed |
| EP-2746301-A1 | Catalyst | Borealis AG (AT) | 2014-06-25 | — | — | EP | disclosed |
| EP-2746301-A1 | Catalyst | Borealis AG (AT) | 2014-06-25 | — | — | EP | disclosed |
| EP-2729479-A1 | CATALYSTS | Borealis AG (AT) | 2014-05-14 | — | — | EP | disclosed |
| WO-2013007650-A1 | CATALYSTS | BOREALIS AG (AT) | 2013-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160024123-A1 | Asymmetrical Ligands | CCRL2, AR, CCR2 | KDM4E 1039/4885CYP1A2 214/4885ADRA1A 1445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.